TP53截短队列患者的中位OS为1181天,而TP53野生型队列(TP53wt)和其他队列的中位OS分别为1474天和1486天(HRTP53truncating=1.61,95%CI:1.22~2.12,p=0.001,图3A)。抗癌管家-康爱管家,我们一起抗癌,治愈癌症不是梦。2年后,大约40%的TP53截短突变患者会发生死亡,而其他两组中约有25%患者发生死亡。此外,与TP53wt...
We have investigated the effects of restoration of wild-type (WT) TP53 activity on the sensitivity of pancreatic cancer cells to: chemotherapy, targeted therapy, as well as, nutraceuticals. Upon introduction of the WT- TP53 gene into the MIA-PaCa-2 pancreatic cancer cell line, the sensitivity ...
TP53 mutations induced by BPDE in Xpa-WT and Xpa-Null human TP53 knock-in (Hupki) mouse embryo fibroblasts Jill E. Kucab a,∗ , Harry van Steeg b , Mirjam Luijten b , Heinz H. Schmeiser c , Paul A. White d , David H. Phillips ...
产品信息 添加产品+ 产品编号 产品名称 期望单价 预购数量 操作 CBP00129 Mu-DdPCR™ WT for TP53 p.R249S c.747G>T 移除 询价说明 个人信息 联系人: 企业名称: 手机: 邮箱: 验证码: 提交信息 联系电话: 4008-750-250 QQ咨询: 在线咨询 咨询时间: 早09:00 - 晚18:00 关于我们 公司介...
Survival results from thetp53wtandtp53mut/abn populations are more favorable than what was observed in the overall population of the SIENDO study, according to Slomovitz. "The update presented at the ASCO Plenary Series demonstrated that the p53 wild-type group, had a progression-free survival...
经过长期随访,截至2024年4月1日,我们发现接受塞利尼索Selinexor治疗的TP53wt患者与接受安慰剂的患者相比,中位PFS(mPFS)存在显著差异。具体来说,塞利尼索Selinexor治疗组的mPFS为28.4个月,而安慰剂组仅为5.2个月(在36.8个月的随访期内,风险比HR为0.44;95%置信区间CI为0.27-0.73)。值得注意的是,无论MMR状态如何,塞...
Selinexor维持可延长TP53wt子宫内膜癌的PFS获益 根据2023年7月美国临床肿瘤学会全体会议上提交的ENGOT-EN5/GOG-3055/SIENDO试验(NCT03555422)的预先指定的3期亚组分析数据,TP53野生型晚期/复发性子宫内膜癌患者在接受维持性selinexor (Xpovio)治疗后,与安慰剂相比,无进展生存期(PFS)得到了持久的改善。
Restoration of p53 pathways by Nutlin-3a in TP53Wt/MDM2Ampl cells.Jane MuretMeriem HasmimIzabela StasikAbdelali JalilAude MallavialleArash NanbakhshLudovic LacroixKaty BillotVéronique BaudJerome Thiery
TP53 mutations induced by BPDE in Xpa-WT and Xpa-Null human TP53 knock-in (Hupki) mouse embryo fibroblasts. Mutat Res 2015; 773:48-62.Kucab JE, van Steeg H, Luijten M, Schmeiser HH, White PA, Phillips DH, et al. TP53 mutations induced by BPDE in Xpa-WT and Xpa-Null human ...
TP53 was previously thought to be a difficult target as it is often mutated, deleted or inactivated on both chromosomes in certain cancers. In the following study, the effects of restoration of wild-type (WT) TP53 activity on the sensitivities of MIA-PaCa-2 pancreatic cancer cells to the ...